Pulse Biosciences Completes Enrollment in 100-Patient Thyroid Nodule Study
MT Newswires Live
Sep 15
Pulse Biosciences (PLSE) said Tuesday that it has completed enrollment in its clinical study evaluating the nPulse Vybrance Percutaneous Electrode System for symptomatic benign thyroid nodules.
The study enrolled 100 patients across three US clinical sites, double the original target of 50 patients, the company said. The first patient completed the final 12-month follow-up last month, it added.
Pulse Biosciences said it plans to present preliminary study data at an upcoming medical society conference, with full data expected after all patients complete 12-month follow-up.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.